Problems › Business Transformation Consulting › Insurance Brokers
Most transformation programmes fail in the diagnosis, and the diagnosis is usually bought from the people who will be paid to deliver the answer. This page works through it for insurance brokers specifically — including an unedited excerpt from a real analysis of an insurance broker.
Most transformation programmes fail in the diagnosis, and the diagnosis is usually bought from the people who will be paid to deliver the answer. Insurance brokers carry a specific bind here — 71 percent of revenue flows through carrier commissions while shifting an incremental 8 percent to fees would require replacing 142 renewal accounts and cut near-term margin by 1.8 to 2.3 points. Until that is priced, 19.0 will keep moving for reasons nobody can attribute, and the debate about programme spend to date will stay a matter of opinion.
A transformation engagement bundles three separable things: finding out what is wrong, deciding what to do about it, and having enough hands to do it. Firms sell them together because that is how the economics work — the diagnostic phase is priced near cost and earns its money by scoping the delivery phase that follows. That is not a scandal, it is a business model, but it has a consequence worth understanding before you sign. The people producing your diagnosis are commercially better off if the diagnosis is large.
The published failure rates for these programmes have hovered around 70% for thirty years, which is itself informative. A discipline that fails most of the time at something it has practised for decades is not failing at execution. It is usually failing earlier, at the point where a genuine question — which parts of this business earn their cost of capital, and which of them can we actually change this year — got converted into a workstream plan before it was answered.
The practical test is whether you can currently name the two or three things that are wrong, in the order you would fix them, with the arithmetic attached. If you can, you have a delivery problem, and buying delivery capacity is a rational purchase. If you cannot, you have a diagnosis problem, and every pound spent on delivery capacity before the diagnosis exists is a pound spent making the wrong change more thoroughly.
Corporate Strategy & Transformation (catalog id t5) is the analysis that produces the first half: what the portfolio actually looks like once cost and capital are allocated honestly, which units are funding which, what changes and in what order. It does not put people on the ground and does not pretend to. Where the honest answer is that you need forty consultants for nine months, it will say so — which is a cheaper way to find that out than the first invoice.
These three together are the signature. One on its own usually points somewhere else.
✓ The word "transformation" is being used before anyone has agreed what is broken
✓ A scoping document exists and a diagnosis does not
✓ The programme has workstreams named after departments rather than after problems
The move that usually makes it worse. Buying the diagnosis from the firm that will bid to deliver the remedy, which reliably produces a diagnosis with a large remedy attached.
It is for you if you run or finance an insurance broker and the word "transformation" is being used before anyone has agreed what is broken. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on an insurance broker. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Kesterline Risk Partners, a sample company profile used for testing rather than a customer — 47.8 million dollars in total revenue from commissions and fees.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Convert 460 commission accounts to fee retainers, funding a $3-5M digital workbench from productivity gains while staying inside the $4.8m investment ceiling.
| Investment required | $3.0-5.0M total (base $3.0M, upside $5.0M for accelerated digital workbench) |
| Expected return | 3.2-4.8× over 36 months on $3-5M investment, based on +$4.2-8.5M incremental fee revenue at 35-45% gross margin versus current 19% operating margin. |
| Revenue, year 1 | $50.1-51.8M total revenue (+$2.3-4.0M incremental fee) |
| Revenue, year 2 | $54.4-57.9M total revenue (+$6.6-10.1M incremental fee) |
| Revenue, year 3 | $58.2-64.8M total revenue (+$10.4-17.0M incremental fee) |
| Exit criteria | Strategy should be reversed if, within 12 months, pilot conversion rate falls below 15% OR incremental churn exceeds 5% OR producer productivity drops below $600k average; OR if, within 24 months, cumulative fee revenue does not reach $6.6M incremental run-rate. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Corporate Strategy & Transformation, one of 29 engagements the platform runs. For insurance brokers it works through 19.0, 91.2, 664 and 31, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
For a mid-market company the diagnostic phase alone is commonly £75k–£250k over six to ten weeks, and the delivery phase that follows is usually several multiples of that. Large-firm day rates run roughly £1,500–£3,500 for a consultant and £4,000–£8,000 for a partner, and a typical team blends the two so the effective rate lands somewhere in the middle. The number that matters is not the day rate, though — it is the ratio of diagnosis to delivery, because that is where the scope is set.
No, and any tool that claims otherwise is selling you something. Software cannot run a programme office, hold a difficult conversation with a divisional MD, or supply forty people for nine months. What it can do is produce the analysis that decides whether you need those things, and what they should be pointed at — which is the part that is most often rushed and most expensive to get wrong.
Buy the diagnosis separately from whoever will deliver, and write the decision down before you take delivery bids. Once the two or three changes are named and the arithmetic is on paper, the delivery tender is a procurement exercise with a fixed brief. Once they are not, the tender sets its own brief, and it is always a larger one.
Materially, yes. 71 percent of revenue flows through carrier commissions while shifting an incremental 8 percent to fees would require replacing 142 renewal accounts and cut near-term margin by 1.8 to 2.3 points — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are 19.0, 91.2, 664, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on 19.0 and 91.2. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.